Bristol Myers Squibb Gets US FDA Approval Of New State-Of-The-Art Cell Therapy Manufacturing Facility In Devens, Massachusetts
Portfolio Pulse from Benzinga Newsdesk
Bristol Myers Squibb (BMY) has received US FDA approval for its new 244,000 square foot cell therapy manufacturing facility in Devens, Massachusetts. The facility is a critical component of BMS' expanding global cell therapy manufacturing footprint.
June 08, 2023 | 8:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bristol Myers Squibb's FDA approval for its new cell therapy manufacturing facility in Devens, MA, will support the company's expanding global cell therapy manufacturing footprint.
The FDA approval for Bristol Myers Squibb's new cell therapy manufacturing facility is a positive development for the company. It will enable BMS to expand its global cell therapy manufacturing footprint, which is crucial for the long-term supply of the company's cell therapy portfolio. This expansion will likely have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100